WO2000025789A1 - Procede pour traiter l'endometriose - Google Patents

Procede pour traiter l'endometriose Download PDF

Info

Publication number
WO2000025789A1
WO2000025789A1 PCT/US1999/025001 US9925001W WO0025789A1 WO 2000025789 A1 WO2000025789 A1 WO 2000025789A1 US 9925001 W US9925001 W US 9925001W WO 0025789 A1 WO0025789 A1 WO 0025789A1
Authority
WO
WIPO (PCT)
Prior art keywords
oxo
imidazo
carbonitrile
substituted
unsubstituted
Prior art date
Application number
PCT/US1999/025001
Other languages
English (en)
Inventor
Allen I. Oliff
Jackson B. Gibbs
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9900160.4A external-priority patent/GB9900160D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Priority to AU12301/00A priority Critical patent/AU1230100A/en
Publication of WO2000025789A1 publication Critical patent/WO2000025789A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé permettant de prévenir et de traiter l'endométriose, les fibromes utérins, la ménométrorragie, et l'hyperplasie endométriale, ce procédé consistant à administrer une quantité efficace d'un inhibiteur de prényl-protéine transférase à un patient mammifère nécessitant un tel traitement.
PCT/US1999/025001 1998-10-29 1999-10-25 Procede pour traiter l'endometriose WO2000025789A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU12301/00A AU1230100A (en) 1998-10-29 1999-10-25 A method of treating endometriosis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10617998P 1998-10-29 1998-10-29
US60/106,179 1998-10-29
GB9900160.4 1999-01-05
GBGB9900160.4A GB9900160D0 (en) 1999-01-05 1999-01-05 A method of treating endometriosis

Publications (1)

Publication Number Publication Date
WO2000025789A1 true WO2000025789A1 (fr) 2000-05-11

Family

ID=26314956

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/025001 WO2000025789A1 (fr) 1998-10-29 1999-10-25 Procede pour traiter l'endometriose

Country Status (2)

Country Link
AU (1) AU1230100A (fr)
WO (1) WO2000025789A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045740A2 (fr) * 1999-12-22 2001-06-28 The Government Of The United States, Department Of Health And Human Services Compositions et procedes de traitement du cancer du sein
WO2002064142A1 (fr) * 2001-02-15 2002-08-22 Janssen Pharmaceutica N.V. Combinaisons d'inhibiteurs de la farnesyle proteine transferase avec agents anti-oestrogene
WO2006006610A1 (fr) * 2004-07-09 2006-01-19 Banyu Pharmaceutical Co., Ltd Derivé d'oxopipérazine
US7632838B2 (en) 2006-02-07 2009-12-15 Wyeth 11-beta HSD1 inhibitors
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones
US9527816B2 (en) 2005-05-10 2016-12-27 Intermune, Inc. Method of modulating stress-activated protein kinase system
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11827627B2 (en) 2021-06-04 2023-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
US11834441B2 (en) 2019-12-06 2023-12-05 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0760239A2 (fr) * 1995-09-01 1997-03-05 Pfizer Inc. Dérivés de pyrrole, d'imidazole et d'indole pour utilisation dans la thérapie du cancer
EP0810223A1 (fr) * 1996-05-28 1997-12-03 Pfizer Inc. Oxindoles substituées par adamantyle, comme agents pharmaceutiques
EP0928788A1 (fr) * 1997-12-30 1999-07-14 Pfizer Products Inc. Dérivés d'imidazolidine-4-one utilisables comme agents anticancéreux
US5948781A (en) * 1997-05-27 1999-09-07 Pfizer Inc Adamantyl substituted oxindoles as pharmaceutical agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0760239A2 (fr) * 1995-09-01 1997-03-05 Pfizer Inc. Dérivés de pyrrole, d'imidazole et d'indole pour utilisation dans la thérapie du cancer
EP0810223A1 (fr) * 1996-05-28 1997-12-03 Pfizer Inc. Oxindoles substituées par adamantyle, comme agents pharmaceutiques
US5948781A (en) * 1997-05-27 1999-09-07 Pfizer Inc Adamantyl substituted oxindoles as pharmaceutical agents
EP0928788A1 (fr) * 1997-12-30 1999-07-14 Pfizer Products Inc. Dérivés d'imidazolidine-4-one utilisables comme agents anticancéreux

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045740A3 (fr) * 1999-12-22 2002-04-25 Geoffrey Clark Compositions et procedes de traitement du cancer du sein
WO2001045740A2 (fr) * 1999-12-22 2001-06-28 The Government Of The United States, Department Of Health And Human Services Compositions et procedes de traitement du cancer du sein
WO2002064142A1 (fr) * 2001-02-15 2002-08-22 Janssen Pharmaceutica N.V. Combinaisons d'inhibiteurs de la farnesyle proteine transferase avec agents anti-oestrogene
JP2004517960A (ja) * 2001-02-15 2004-06-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ
WO2006006610A1 (fr) * 2004-07-09 2006-01-19 Banyu Pharmaceutical Co., Ltd Derivé d'oxopipérazine
US10010536B2 (en) 2005-05-10 2018-07-03 Intermune, Inc. Method of modulating stress-activated protein kinase system
US9527816B2 (en) 2005-05-10 2016-12-27 Intermune, Inc. Method of modulating stress-activated protein kinase system
US7632838B2 (en) 2006-02-07 2009-12-15 Wyeth 11-beta HSD1 inhibitors
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9290450B2 (en) 2008-06-03 2016-03-22 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
USRE47142E1 (en) 2008-06-03 2018-11-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9675593B2 (en) 2012-10-02 2017-06-13 Intermune, Inc. Anti-fibrotic pyridinones
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones
US10376497B2 (en) 2012-10-02 2019-08-13 Intermune, Inc. Anti-fibrotic pyridinones
US10898474B2 (en) 2012-10-02 2021-01-26 Intermune, Inc. Anti-fibrotic pyridinones
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
US10544161B2 (en) 2014-04-02 2020-01-28 Intermune, Inc. Anti-fibrotic pyridinones
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11834441B2 (en) 2019-12-06 2023-12-05 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
US11919887B2 (en) 2019-12-06 2024-03-05 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
US11827627B2 (en) 2021-06-04 2023-11-28 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels

Also Published As

Publication number Publication date
AU1230100A (en) 2000-05-22

Similar Documents

Publication Publication Date Title
WO2000051611A1 (fr) Inhibiteurs de la prenyle-proteine transferase
WO2000051614A1 (fr) Inhibiteurs de prenyl-proteine transferases
WO2001060369A1 (fr) Inhibiteurs de la prenyl-proteine transferase
AU4845099A (en) Inhibitors of prenyl-protein transferase
WO2000059930A1 (fr) Une methode pour le traitement du cancer
WO2000001382A1 (fr) Inhibiteurs de prenyl-proteine transferase
WO2000025789A1 (fr) Procede pour traiter l'endometriose
AU9121398A (en) Inhibitors of prenyl-protein transferase
WO2001060368A1 (fr) Inhibiteurs de la prenyle proteine transferase
WO2000001701A1 (fr) Inhibiteurs de prenyl-proteine transferase
AU3386600A (en) Inhibitors of prenyl-protein transferase
WO2001060458A2 (fr) Inhibiteurs de la prenyl-proteine transferase
WO2000051547A2 (fr) Inhibiteurs de prenyle proteine transferase
WO2000016778A1 (fr) Procede de traitement du cancer
US6355643B1 (en) Inhibitors of prenyl-protein transferase
WO2001077114A1 (fr) Inhibiteurs de la prenyl-proteine transferase
WO2001051125A1 (fr) Inhibiteurs de la prenyl-proteine transferase
WO1999010329A1 (fr) Inhibiteurs de prenyl-proteine-transferase
WO2000016626A1 (fr) Methode de traitement du cancer
WO2000075135A1 (fr) Inhibiteurs biaryliques de la prenyl-proteine transferase
AU8921398A (en) A method of treating cancer
WO2001077116A1 (fr) Inhibiteurs de prenyl-proteine transferase
WO2001007051A1 (fr) Inhibiteurs de prenyl-proteine transferase
AU9205998A (en) A method of treating cancer

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 12301

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase